Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Teva

Olmesartan medoxomil, amlodipine besilate and hydrochlorothiazide, the active ingredients in Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Teva, are a combination antihypertensive presented as a tablet formulation for oral use. They are indicated for the management of high blood pressure in adult patients, helping to lower cardiovascular risk.

GNH USA supplies Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil/amlodipine besilate/hydrochlorothiazide is a combination antihypertensive used to treat hypertension through multiple mechanisms.

- Essential hypertension: lowers systolic and diastolic blood pressure when monotherapy is insufficient. - Secondary hypertension: provides additional control in patients with hypertension due to renal or endocrine causes. - Hypertension with fluid retention: combines vasodilation and diuresis to reduce blood volume and vascular resistance.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache, often mild and transient. - Peripheral edema, typically swelling of the ankles. - Flushing or warmth sensation.

Serious or Rare Side Effects: - Angioedema or severe swelling of the face, lips, or throat. - Marked hypotension leading to fainting. - Acute renal impairment or significant rise in serum creatinine. - Electrolyte disturbances such as severe hyponatremia or hyperkalemia. - Hepatic dysfunction presenting as jaundice or elevated liver enzymes.

Before initiating therapy, patients should be evaluated for renal function, electrolyte balance, and potential drug interactions.

- Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during treatment. - Electrolyte surveillance: monitor potassium and sodium levels, especially with diuretic component. - Pregnancy and lactation: avoid use unless clearly needed, as safety data are limited. - Hepatic impairment: use with caution in patients with severe liver disease. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan medoxomil/amlodipine besilate/hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: concomitant use can raise lithium levels and toxicity. - NSAIDs: can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - ACE inhibitors or other ARBs: additive blood‑pressure lowering effect, monitor for hypotension. - CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase amlodipine concentrations. - CYP2C9 inhibitors (e.g., fluconazole): can raise hydrochlorothiazide levels, watch electrolytes.